These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29203982)

  • 1. Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers-a Study from Indian Regional Cancer Centre.
    Smitha CS; Suresh BMC; Linu JA; Lakshmaiah KC; Govind BK; Lokanatha D; Pretesh RK
    Indian J Surg Oncol; 2017 Dec; 8(4):511-513. PubMed ID: 29203982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
    Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
    Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS mutations in patients with colorectal cancer in Libya.
    Abudabous A; Drah M; Aldehmani M; Parker I; Alqawi O
    Mol Clin Oncol; 2021 Oct; 15(4):197. PubMed ID: 34462653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
    Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
    Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.
    Veldore VH; Rao MR; Prabhudesai SA; Tejaswi R; Kakara S; Pattanayak S; Krishnamoorthy N; Tejaswini BN; Hazarika D; Gangoli A; Rahman SM; Dixit J; Naik R; Diwakar RB; Satheesh CT; Shashidhara HP; Patil S; Gopinath KS; Kumar BS
    Indian J Cancer; 2014; 51(4):531-7. PubMed ID: 26842186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of the Ion Torrent PGM next generation sequencing for analysis of the most commonly mutated genes among patients with colorectal cancer in India.
    Mehra S; Tiwari AK; Mehta SP; Sachdev R; Rajvanshi C; Chauhan R; Saini A; Vaid A
    Indian J Cancer; 2022; 59(2):218-222. PubMed ID: 33753628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].
    Mazurenko NN; Gagarin IM; Tsyganova IV; Mochal'nikova VV; Breder VV
    Vopr Onkol; 2013; 59(6):751-5. PubMed ID: 24624786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Evaluation of IntelliPlex™ KRAS G12/13 Mutation Kit for Detection of KRAS Mutations in Codon 12 and 13: A Novel Multiplex Approach.
    Chen CL; Chen CK; Ho CL; Chi WM; Yeh CH; Hu SP; Friebe P; Palmer S; Huang CS
    Mol Diagn Ther; 2019 Oct; 23(5):645-656. PubMed ID: 31347028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive biomarkers for anti-EGFR antibodies].
    Bando H; Yoshino T
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1618-25. PubMed ID: 23152013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
    Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
    Vaughn CP; Zobell SD; Furtado LV; Baker CL; Samowitz WS
    Genes Chromosomes Cancer; 2011 May; 50(5):307-12. PubMed ID: 21305640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
    Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
    Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational status of KRAS and MMR genes in a series of colorectal carcinoma cases.
    Cionca FL; Dobre M; Dobrea CM; Iosif CI; Comănescu MV; Ardeleanu CM
    Rom J Morphol Embryol; 2018; 59(1):121-129. PubMed ID: 29940619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H; Eshima K
    Eur J Cancer; 2011 Sep; 47(13):1946-54. PubMed ID: 21531130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Eur J Cancer; 2016 Mar; 55():122-30. PubMed ID: 26812186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.